Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Radiotherapy with or without Maintenance in Oropharynx Cancer
NCT00251381Phase 2Unknown
- Sponsor
- TFS HealthScience
- Start
- Nov 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by TFS HealthScience. Primary endpoint: 1-year rate of Locoregional Disease Control. Status: unknown.
02
Drugs
cetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT00251381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251381.